

UNIVERSITI TEKNOLOGI MARA

**NEUROPROTECTIVE EFFECT AND
MOLECULAR MECHANISMS OF
ACTION OF MAGNESIUM
ACETYLTaurate AGAINST
NMDA-INDUCED RETINAL INJURY
IN RATS: FOCUS ON CALCIUM
REGULATED PROTEINS**

AZLIANA JUSNIDA AHMAD JAFRI

PhD

January 2020

AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the results of my own work, unless otherwise indicated or acknowledged as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student : Azliana Jusnida Binti Ahmad Jafri

Student I.D. No. : 2014384847

Programme : Doctor of Philosophy (Physiology)- MD954

Faculty : Medicine

Thesis Title : Neuroprotective Effect and Molecular Mechanisms of
Action of Magnesium Acetyltaurate against NMDA-
Induced Retinal Injury in Rats: Focus on Calcium
Regulated Proteins

Signature of Student :

Date : January 2020

ABSTRACT

The excitotoxicity refers to excessive calcium influx intracellularly due to stimulation of glutamate receptors particularly the NMDA subtypes. This triggers apoptosis via calpain, calcineurin, CaMKII activation and cabin 1 inhibition. Altered expression of these Ca^{2+} regulated proteins cause increased retinal oxidative stress and nitric oxide synthase (NOS) expression. Altered NOS expression leads to production of nitrogen free radicals that further perpetuate the oxidative stress, activate the caspases and this culminates to apoptosis. Retinal ganglion cell (RGC) apoptosis is the hallmark feature of glaucoma and excitotoxic injury is the prominent pathophysiological mechanism. None of the current antiglaucoma medications counteract excitotoxicity but act only by reducing elevated intraocular pressure (IOP). Elevated IOP is the major risk factor for glaucoma, however, its lowering does not always prevent RGC apoptosis. Since, magnesium (Mg) is a natural calcium antagonist and taurine also possesses Ca^{2+} antagonistic and antioxidant properties, current study investigated the neuroprotective effect of Magnesium Acetyltaurate (MgAT), a combined salt of Mg and taurine, against NMDA-induced RGC apoptotic in *Sprague Dawley* rats. Animals weighing 200-250 g were divided into 5 groups. Groups 1 and 2 received PBS and NMDA, respectively, intravitreally. Groups 3, 4 and 5 received MgAT intravitreally as pre-, co- and post-treatment with NMDA. Rats were sacrificed 7 days post-injection and eyes were enucleated for histopathological examination of retina, detection of TUNEL positive retinal cells, expressions of 3 NOS isoforms and retinal oxidative stress. MgAT pre-treatment most prominently protected against NMDA-induced retinal injury by restoring the expression of NOS isoforms, lowering the nitrosative and oxidative stress and preserving the retinal morphology. In the next part of study, the neuroprotective effect of taurine alone was studied using the same parameters. Although pre-treatment with taurine provided neuroprotection against NMDA-induced injury, the same effects of pre-treatment with MgAT was significantly greater than taurine alone. Therefore, in the subsequent study, mechanisms of neuroprotective effect of MgAT pre-treatment against NMDA-induced retinal injury involving expression of calcium regulated proteins were investigated. It was observed that pre-treatment with MgAT abolishes the NMDA-induced increase in the retinal expression of calpain 1 and CaMKII and decreases the expression of cabin 1. To determine if MgAT pre-treatment could prolong the RGC survival, retrograde labelling of RGC was done using fluorogold as a neuronal tracer. Additionally, retinal sections were subjected to Brn3a immunostaining. Both the retrograde labelling and Brn3a staining specifically detected live RGCs, hence indicating the RGC survival. Both experiments showed significantly enhanced RGC survival in the MgAT pre-treatment group compared to NMDA treated group. Lastly, rats were subjected to visual function test to determine the functional outcome of the effects of MgAT. The visual recognition test using open field and Morris water maze test showed that pre-treatment with MgAT protects against NMDA-induced impairment of the visual functions. In conclusion, the current study showed that the pre-treatment with MgAT prevents NMDA-induced loss of retinal cells and preserves retinal morphology by reducing retinal nitrosative and oxidative stress more effectively than taurine alone. Mechanisms underlying these effects of MgAT are likely to involve restoration of NMDA-induced changes in the expression of calpain 1, CaMKII and cabin 1. These effects of MgAT was associated with greater RGC survival and improved visual functions. Further studies are needed to fully explore the potential of MgAT as an antiglaucoma agent.

ACKNOWLEDGEMENT

In the name of Allah, Ar Rahman (the Most Compassionate) and Ar Rahim (the Most Merciful). First and foremost, Alhamdulillah, all praise the Almighty for giving me the strength and perseverance to finally complete my doctoral journey.

To my supervisor and my mentor, Prof Dr Renu Agarwal, I am truly blessed with your immeasurable guidance since I began my journey. I cannot thank you enough for being patient while I was still learning and when I staggered across difficulties and challenges throughout this journey. I would like to give you the biggest appreciation for believing in me and pushing me to do the best and because of this, I am a different student and researcher today than who I was before. Thank you, Prof, for being a supervisor, my mentor, a mother and a friend to me for the past 5 years. Not to forget, to my co-supervisors; who have worked with me since day 1, in making sure every flaw is perfected, Assoc Prof Dr Igor Iezhitsa and Prof Nafeeza Mohd Ismail, thank you for the countless advices, supports, ideas and wisdoms during my study.

To my backbone, Roselinda Binti Ramli, my mother. The reason I chose this journey is because of you. For all the hardships that you went through alone to provide for me since I was a child. This is for you. Thank you for giving me support and unconditional love until today. To my sisters and brother; Jufian, Ammielyya, Alliena and Ain, thank you for being my pillows and rocks everyday especially during my struggles and hardships.

To my soon to be other half, Jamie Price, thank you for giving me comfort and undeniable encouragement every day. Thank you for all the financial support in making sure I have what I need in order to succeed this journey. Thank you for listening to my presentation countless times and giving the emotional support during the tough time and for making sure I am happy every day.

I am also indebted to my forever friends; Natasha, Lidawani, Ainsya, Normie, Aizuddin and Adrian. Without each and every one of you, this journey would have felt insurmountable to go through alone. I am lucky and proud to be with you guys at every single step since we started this journey together.

To my seniors, Dr Hafiza and Dr Alimah, I am so grateful to have both of you when I first joined the Faculty of Medicine, UiTM Sg Buloh. Thank you for all the knowledge and leadership when I was lacking with research experiences. Thank you for always welcoming me when I had questions, doubts and helping me to be a better researcher.

To my late step father, Md Ali Bin Mahadi, when I started this journey I lost you. Thank you for believing in me when I told you that I wanted to do this.

Last but not the least, thank you to Dr Anna, Dr Syafika, Dr Fahitah and all IMMB and LACU officers for their numerous information, care and supports. Another thanks to funding agencies during my PhD journey (Grant number: 600-IRMI/DANA 5/3/Bestari (P) (003/2018), 600-IRMI/DANA 5/3/BESTARI (006/2017) and 600-RMI/RAGS 5/3 (103/2013).

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR’S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xiv
LIST OF FIGURES	xvi
LIST OF ABBREVIATIONS	xxi
CHAPTER ONE: INTRODUCTION	1
1.1 Background of Study	1
1.2 Problem Statement	3
1.3 Research Questions	4
1.4 Hypothesis	4
1.5 Objectives	4
1.5.1 General Objective	4
1.5.2 Specific Objectives	5
1.6 Scope and Limitations of Study	5
CHAPTER TWO: LITERATURE REVIEW	7
2.1 Glaucoma: History, Definition and Etiology	7
2.1.1 History	7
2.2 Glaucoma: Prevalence, Classification and Risk Factors	9
2.2.1 Primary Glaucoma	9
2.2.1.1 <i>Primary open angle glaucoma (POAG)</i>	9
2.2.2 Primary Angle Closure Glaucoma (PACG)	10
2.2.2.1 <i>Primary congenital glaucoma (PCG)</i>	11
2.2.3 Secondary Glaucoma	11
2.3 Structure of Eye and Parts Affected by Glaucoma	12